Evaluation of incidence of thrombosis and bleeding in medical floor COVID-19 patients at a community hospital

Giselle Chahili  
*Baptist Hospital of Miami*, gisellech@baptisthealth.net

Frank C. Moreno Exposito  
*Baptist Hospital of Miami*, frankmore@baptisthealth.net

Heidi Clarke  
*Baptist Hospital of Miami*, heidic@baptisthealth.net

Erika Dittmar  
*Baptist Hospital of Miami*, ErikaDi@baptisthealth.net

Follow this and additional works at: [https://scholarlycommons.baptisthealth.net/se-all-publications](https://scholarlycommons.baptisthealth.net/se-all-publications)

Part of the Cardiovascular Diseases Commons, Pharmacy and Pharmaceutical Sciences Commons, Respiratory Tract Diseases Commons, and the Virus Diseases Commons

Citation  
Chahili, Giselle; Moreno Exposito, Frank C.; Clarke, Heidi; and Dittmar, Erika, "Evaluation of incidence of thrombosis and bleeding in medical floor COVID-19 patients at a community hospital" (2020). All Publications. 3759.  
[https://scholarlycommons.baptisthealth.net/se-all-publications/3759](https://scholarlycommons.baptisthealth.net/se-all-publications/3759)

This Conference Poster – Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.
Evaluation of incidence of thrombosis and bleeding in medical floor COVID-19 patients at a community hospital
Giselle Chahili, Pharm.D., Frank C. Moreno, Pharm.D., Heidi Clarke, Pharm.D., BCCCP, Erika Dittmar, Pharm.D., BCPS
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

BACKGROUND
- Individuals affected by Coronavirus Disease 2019 (COVID-19) are more prone to coagulopathy, a complication associated with disseminated intravascular coagulation (DIC) and a poor overall prognosis.1,2
- Incidence of venous thromboembolism (VTE) in COVID-19 increases with certain medical conditions such as obesity, heart disease (ex. atrial fibrillation), history of myocardial infarction or stroke, and thrombophilia. Other risk factors associated with worse outcomes are elevated D-dimer and increased inflammatory markers such as, interleukin-6 (IL-6), lactate dehydrogenase (LDH), and ferritin levels.3
- Due to an alarming trend in stroke and death among this patient population, anticoagulation therapy is recommended in all patients who do not have a contraindication.1,3
- Early during the pandemic, societal guidelines recommended using full dose anticoagulation in critically ill patients without a diagnosed indication. Later on, an increased incidence of bleeding, intermediate dosing (ex. enoxaparin 30-40mg twice a day) was recommended.1,7
- Risk of VTE and major bleeding in COVID-19 patients is still unknown
- The intent of this project is to evaluate anticoagulation dosing used over a six-month period and determine incidence of VTE and bleeding in COVID-19 positive patients at Baptist Hospital of Miami

OBJECTIVES
- Describe the incidence of thrombosis, bleeding events, and 30-day readmission rates in adult COVID-19 patients

METHODS
- Study design:
  - Single-center, retrospective chart review of patients admitted to Baptist Hospital of Miami due to COVID-19 from 03/01/2020 to 08/31/2020
  - Subjects were divided into two groups
    - Early group: hospitalized March-May
    - Late group: hospitalized June-Aug
- Inclusion criteria:
  - Individuals ≥ 18 years old
  - COVID-positive test
- Admission to the general medical floor or step-down
- Exclusion criteria:
  - Pregnancy
  - Intensive Care Unit (ICU) admission
- Primary outcome: Incidence of thrombosis
- Defined as deep vein thrombosis (DVT), pulmonary embolism (PE), acute ischemic stroke (AIS), or myocardial infarction (MI)
- Primary safety outcome: Incidence of bleeding
- Defined as bleeding from any site
- Secondary outcome: 30-day readmission

RESULTS

<table>
<thead>
<tr>
<th>Baseline Characteristics (N=200)</th>
<th>Early COVID (n=100)</th>
<th>Late COVID (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age (yrs)</td>
<td>61</td>
<td>64</td>
</tr>
<tr>
<td>Gender, %</td>
<td>Female</td>
<td>52</td>
</tr>
<tr>
<td>Race, %</td>
<td>White Hispanic</td>
<td>74</td>
</tr>
<tr>
<td>Mean BMI (Kg/m²)</td>
<td>29.8</td>
<td>29.4</td>
</tr>
<tr>
<td>Mobility, %</td>
<td>No limitation</td>
<td>64</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>Former smoker</td>
<td>17</td>
</tr>
<tr>
<td>Comorbidities, %</td>
<td>Hypertension</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>AIS or MI</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Hyperlipidemia</td>
<td>31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary Outcome (N=200)</th>
<th>Early COVID (n=100)</th>
<th>Late COVID (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombosis, %</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Bleeding, %</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>30-day readmission, %</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>• PE, %</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>• DVT, %</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>• MI, %</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>• AIS, %</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COVID Treatment (N=200)</th>
<th>Early COVID (n=100)</th>
<th>Late COVID (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine, %</td>
<td>76</td>
<td>1</td>
</tr>
<tr>
<td>Tocilizumab, %</td>
<td>10</td>
<td>63</td>
</tr>
<tr>
<td>Remdesivir, %</td>
<td>0</td>
<td>67</td>
</tr>
<tr>
<td>Convalescent Plasma, %</td>
<td>0</td>
<td>67</td>
</tr>
<tr>
<td>Steroids, %</td>
<td>34</td>
<td>91</td>
</tr>
</tbody>
</table>

COVId Treatment (N=200)

LITMATIONS
- Small sample size
- Retrospective study design
- Documentation in the medical records was not complete/thorough
- Several pertinent laboratory values were not monitored, especially early during the pandemic
- Only assessed readmission within Baptist Hospital of Miami

CONCLUSION
- Baseline characteristics were similar between early and late groups
- COVID treatment strategies differed significantly between the two arms
- Anticoagulation dosing was similar between early and late groups
- Majority of patients received prophylactic dosing. 18 patients received treatment dosing due to a diagnosed indication. No patients received intermediate dosing or treatment dosing without a diagnosed indication
- 3 patients in the late COVID group had a thrombotic event (2 PE, 1DVT)
- 1 patient who received prophylactic dosing had mild hemoptysis not requiring pharmacologic interventions
- 15 patients were readmitted within 30 days (2 PE, 1DVT)
- Prophylactic dosing did not increase risk of thrombosis or bleeding even though most patients had elevated D-dimer and inflammatory markers suggestive of VTE risk

DISCUSSION
- This is a retrospective chart review comparing prescribing patterns of anticoagulation between early and late COVID groups
- Anticoagulation at prophylactic doses does not seem to increase risk of thrombosis or bleeding significantly in patients admitted to medical floors at Baptist Hospital of Miami
- Moreover, 30-day readmissions were mostly due to causes other than thrombosis and bleeding in the majority of our patients

REFERENCES

DISCLOSURES
- All authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have direct or indirect interest in the subject matter of this presentation.